iBio announces USPTO issued patent on AI-engineered epitope discovery

iBio announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 11,545,238, entitled "Machine Learning Method For Protein Modelling To Design Engineered Peptides," which covers a machine learning model developed to design engineered epitopes which allow precise steering of therapeutic antibodies towards specific regions of a target protein. "We are thrilled to be issued this U.S. patent, which solidifies our position as a leader in AI-driven drug discovery, and whose claims guarantee broad coverage of our proprietary, epitope-steering antibody discovery engine," said Martin Brenner, DVM. Ph.D., iBio‘s Chief Scientific Officer. "In addition to marking an important milestone as we transform iBio into an AI-powered biotech company, this patent provides us with a competitive advantage as we continue to build our differentiated pipeline, with benefits that extend to our potential future partners."